These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
485 related articles for article (PubMed ID: 25811961)
1. A hybrid platinum drug dichloroacetate-platinum(II) overcomes cisplatin drug resistance through dual organelle targeting. Zhang Y; Guo G; Ma B; Du R; Xiao H; Yang X; Li W; Gao Y; Li Y; Jing X Anticancer Drugs; 2015 Aug; 26(7):698-705. PubMed ID: 25811961 [TBL] [Abstract][Full Text] [Related]
2. Synthesis of trans-bis-(2-hydroxypyridine)dichloroplatinum(II) and its activity in human ovarian tumour models. Deqnah N; Yu JQ; Beale P; Fisher K; Huq F Anticancer Res; 2012 Jan; 32(1):135-40. PubMed ID: 22213298 [TBL] [Abstract][Full Text] [Related]
3. Gene-specific repair of Pt/DNA lesions and induction of apoptosis by the oral platinum drug JM216 in three human ovarian carcinoma cell lines sensitive and resistant to cisplatin. O'Neill CF; Koberle B; Masters JR; Kelland LR Br J Cancer; 1999 Dec; 81(8):1294-303. PubMed ID: 10604725 [TBL] [Abstract][Full Text] [Related]
4. Mitaplatin, a potent fusion of cisplatin and the orphan drug dichloroacetate. Dhar S; Lippard SJ Proc Natl Acad Sci U S A; 2009 Dec; 106(52):22199-204. PubMed ID: 20007777 [TBL] [Abstract][Full Text] [Related]
5. In vitro studies on the mechanisms of oxaliplatin resistance. Hector S; Bolanowska-Higdon W; Zdanowicz J; Hitt S; Pendyala L Cancer Chemother Pharmacol; 2001 Nov; 48(5):398-406. PubMed ID: 11761458 [TBL] [Abstract][Full Text] [Related]
6. Quantitative evaluation of cellular uptake, DNA incorporation and adduct formation in cisplatin sensitive and resistant cell lines: Comparison of different Pt-containing drugs. Corte-Rodríguez M; Espina M; Sierra LM; Blanco E; Ames T; Montes-Bayón M; Sanz-Medel A Biochem Pharmacol; 2015 Nov; 98(1):69-77. PubMed ID: 26352094 [TBL] [Abstract][Full Text] [Related]
7. Mitaplatin increases sensitivity of tumor cells to cisplatin by inducing mitochondrial dysfunction. Xue X; You S; Zhang Q; Wu Y; Zou GZ; Wang PC; Zhao YL; Xu Y; Jia L; Zhang X; Liang XJ Mol Pharm; 2012 Mar; 9(3):634-44. PubMed ID: 22289032 [TBL] [Abstract][Full Text] [Related]
8. Activation of mitochondrial oxidation by PDK2 inhibition reverses cisplatin resistance in head and neck cancer. Roh JL; Park JY; Kim EH; Jang HJ; Kwon M Cancer Lett; 2016 Feb; 371(1):20-9. PubMed ID: 26607904 [TBL] [Abstract][Full Text] [Related]
9. Synthesis of a monofunctional platinum compound and its activity alone and in combination with phytochemicals in ovarian tumor models. Arzuman L; Beale P; Yu JQ; Proschogo N; Huq F Anticancer Res; 2014 Dec; 34(12):7077-90. PubMed ID: 25503135 [TBL] [Abstract][Full Text] [Related]
10. Analysis of cytotoxicities of platinum compounds. Goodisman J; Hagrman D; Tacka KA; Souid AK Cancer Chemother Pharmacol; 2006 Jan; 57(2):257-67. PubMed ID: 16028101 [TBL] [Abstract][Full Text] [Related]
11. Cellular accumulation and cytotoxicity of macromolecular platinum complexes in cisplatin-resistant tumor cells. Garmann D; Warnecke A; Kalayda GV; Kratz F; Jaehde U J Control Release; 2008 Oct; 131(2):100-6. PubMed ID: 18691617 [TBL] [Abstract][Full Text] [Related]
12. Synthesis and antitumour activity of a new trinuclear platinum compound [{cis-PtCl(NH3)2μ {trans-Pt(3-hydroxypyridine)2H2N(CH2)5NH2)2}] Cl4 in human ovarian cancer cells. Hamad SA; Beale P; Yu JQ; Huq F Anticancer Res; 2014 Apr; 34(4):1923-9. PubMed ID: 24692727 [TBL] [Abstract][Full Text] [Related]
13. Role of carrier ligand in platinum resistance of human carcinoma cell lines. Schmidt W; Chaney SG Cancer Res; 1993 Feb; 53(4):799-805. PubMed ID: 8428361 [TBL] [Abstract][Full Text] [Related]
14. Platinum(II) carboxylato complexes containing 7-azaindoles as N-donor carrier ligands showed cytotoxicity against cancer cell lines. Štarha P; Trávníček Z; Pazderová L; Dvořák Z J Inorg Biochem; 2016 Sep; 162():109-116. PubMed ID: 27350081 [TBL] [Abstract][Full Text] [Related]
15. Synthesis, characterization, and biological evaluation of new tetrazole-based platinum(II) and palladium(II) chlorido complexes--potent cisplatin analogues and their trans isomers. Serebryanskaya TV; Yung T; Bogdanov AA; Shchebet A; Johnsen SA; Lyakhov AS; Ivashkevich LS; Ibrahimava ZA; Garbuzenco TS; Kolesnikova TS; Melnova NI; Gaponik PN; Ivashkevich OA J Inorg Biochem; 2013 Mar; 120():44-53. PubMed ID: 23305964 [TBL] [Abstract][Full Text] [Related]
16. Potentiation of mitochondrial dysfunction in tumor cells by conjugates of metabolic modulator dichloroacetate with a Pt(IV) derivative of oxaliplatin. Zajac J; Kostrhunova H; Novohradsky V; Vrana O; Raveendran R; Gibson D; Kasparkova J; Brabec V J Inorg Biochem; 2016 Mar; 156():89-97. PubMed ID: 26780576 [TBL] [Abstract][Full Text] [Related]
17. Platinum(IV) complexes conjugated with phenstatin analogue as inhibitors of microtubule polymerization and reverser of multidrug resistance. Huang X; Huang R; Gou S; Wang Z; Liao Z; Wang H Bioorg Med Chem; 2017 Sep; 25(17):4686-4700. PubMed ID: 28728896 [TBL] [Abstract][Full Text] [Related]
18. Platinum(IV) complex with adamantylamine overcomes intrinsic resistance to cisplatin in ovarian cancer cells. Horváth V; Blanárová O; Svihálková-Sindlerová L; Soucek K; Hofmanová J; Sova P; Kroutil A; Fedorocko P; Kozubík A Gynecol Oncol; 2006 Jul; 102(1):32-40. PubMed ID: 16364413 [TBL] [Abstract][Full Text] [Related]
19. Studies on synthesis, activity and binding with DNA of a new trinuclear platinum compound [{trans-PtCl(NH3)2}2{trans-Pt(thiazole)2}{H2N(CH2)(6NH2}2]Cl3(NO3). Al-Shuneigat J; Qing Y; Beale P; Fisher K; Huq F Med Chem; 2011 Jan; 7(1):1-8. PubMed ID: 21235513 [TBL] [Abstract][Full Text] [Related]
20. Expression of p53 in cisplatin-resistant ovarian cancer cell lines: modulation with the novel platinum analogue (1R, 2R-diaminocyclohexane)(trans-diacetato)(dichloro)-platinum(IV). Hagopian GS; Mills GB; Khokhar AR; Bast RC; Siddik ZH Clin Cancer Res; 1999 Mar; 5(3):655-63. PubMed ID: 10100719 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]